Pharmaceutical company Moderna (MRNA) has seen its stock slump in recent months. The share price peaked at $150 in early ...
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...
Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress in individualized cancer therapies. Vandana Singh Benzinga Bulls And ...
Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...
On Wednesday, Moderna Inc (MRNA) stock saw a decline, ending the day at $54.72 which represents a decrease of $-0.50 or -0.91% from the prior close of $55.22. The stock opened at $54.37 and touched a ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal ...
Needham analyst Joseph Stringer has maintained their neutral stance on MRNA stock, giving a Hold rating on October 28. Joseph Stringer has ...
The company's stock price took a big hit in September after its R&D Day when it announced cuts to R&D funding and a pipeline shakeup. Adding to the misery, Moderna (NASDAQ:MRNA) was the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback